Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
21/05/2026 23:06
May 21 (Reuters) - Biogen BIIB.O and Denali Therapeutics DNLI.O said on Thursday they will discontinue development of their Parkinson's drug it failed to meet the main goal in a mid-to-late stage study. (Reporting by Sahil Pandey in Bengaluru; Editing by Shailesh Kuber) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova